Biotech
Vir Biotechnology
Vir Biotechnology raises $250M Series E at $3.3B valuation
$250M
Total Raised
Series E
Latest Round
2016
Founded
500+
Employees
499 Illinois Street, San Francisco, CA 94158
1 min read
Quick Facts
Valuation
$3.3B
Latest Round Size
$250M
Latest Round Date
January 2024
Vir Biotechnology: Series E Funding Round
Vir Biotechnology has successfully raised $250M in Series E funding, reaching a valuation of $3.3B.
Company Overview
Infectious disease treatment development
Funding Details
The Series E round was led by SoftBank Vision Fund, with participation from Arch Venture Partners, ARCH Venture Partners, Intermediate Capital Group.
Company Information
- Headquarters: 499 Illinois Street, San Francisco, CA 94158
- Founded: 2016
- Employees: 500+
- Category: Biotech
Investment
Vir Biotechnology plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series E
- Arch Venture Partners: Verified investor in Series E
- ARCH Venture Partners: Verified investor in Series E
- Intermediate Capital Group: Verified investor in Series E
Key Investors
SoftBank Vision Fund
Lead Investor
Verified investor in Series E
Arch Venture Partners
Investor
Verified investor in Series E
ARCH Venture Partners
Investor
Verified investor in Series E
Intermediate Capital Group
Investor
Verified investor in Series E
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M